Roche?s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
- At three years, 88.3% of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared to 77.0% treated with Herceptin, an 11.3% improvement
- People who have residual disease after neoadjuvant treatment have a worse prognosis than those with no detectable disease
- Data from the phase III KATHERINE study will be submitted to health authorities globally, including the US Food and Drug Administration and European Medicines Agency
- Results are being presented at the 2018 San Antonio Breast Cancer Symposium, featured in the press programme and simultaneously published in the New England Journal of Medicine on Wednesday, 5 December 2018